Drug Trial Radar · NCT07072585
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,708
Planned (sponsor's estimate)
Start
Aug 28, 2026
Primary completion
Sep 1, 2035
Study completion Sep 1, 2035
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- First posted
- Jul 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 365 days, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II/III trial tests the addition of daratumumab to chemotherapy for treating patients with newly-diagnosed T-ALL and T-LL. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with daratumumab may kill more cancer cells.
Conditions
- Stage II T Lymphoblastic Leukemia/Lymphoma
- Stage III T Lymphoblastic Leukemia/Lymphoma
- Stage IV T Lymphoblastic Leukemia/Lymphoma
- T Acute Lymphoblastic Leukemia
- T Lymphoblastic Lymphoma
Interventions
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Bone ScanProcedure
Undergo bone scan
BortezomibDrug
Given IV or SC
Calaspargase PegolDrug
Given IV
Computed TomographyProcedure
Undergo CT
CyclophosphamideDrug
Given IV
CytarabineDrug
Given IT or IV or SC
DaratumumabBiological
Given IV
Daunorubicin HydrochlorideDrug
Given IV
DexamethasoneDrug
Given PO or IV
Doxorubicin HydrochlorideDrug
Given IV
Echocardiography TestProcedure
Undergo ECHO
Lumbar PunctureProcedure
Under lumbar puncture
Magnetic Resonance ImagingProcedure
Undergo MRI
Mercaptopurine Oral SuspensionDrug
Given PO
MethotrexateDrug
Given IT or IV or PO
MethylprednisoloneDrug
Given IV
NelarabineDrug
Given IV
PegaspargaseDrug
Given IV or IM
Positron Emission TomographyProcedure
Undergo PET or PET-CT
PrednisoloneDrug
Given PO or IV
PrednisoneDrug
Given PO or IV
Questionnaire AdministrationOther
Ancillary studies
Radiation TherapyRadiation
Undergo radiation therapy
Therapeutic HydrocortisoneDrug
Given IT
ThioguanineDrug
Given PO
Ultrasound ImagingProcedure
Undergo ultrasound
Vincristine SulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS) in patients with newly diagnosed T-cell lymphoblastic leukemia (T-ALL)Time frame: From date of randomization (randomization conducted at the end of induction [EOI]) to date of first event (consolidation failure, interim maintenance failure, relapse, secondary malignant neoplasm [SMN], death from any cause), assessed up to 4 years
- EFS in patients with newly diagnosed T-cell lymphoblastic lymphoma (T-LL)Time frame: From date of randomization (randomization conducted at the EOI) to date of first event (consolidation failure, relapse, progressive disease, SMN, death from any cause), assessed up to 4 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.